Beta-glucan und cd40-agonist-kombinationsimmuntherapie zur behandlung von bauchspeicheldrüsenkrebs

AT1914732TUndetermined Publication Date: 2026-05-15HIBERCELL INC +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: AT2019766563T
Authority / Receiving Office: AT · AT
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2018-03-13
Filing Date: 2019-03-13
Publication Date: 2026-05-15
Estimated Expiration: 2039-03-13

Application Information

Patent Timeline

13 Mar 2018

Priority

13 Mar 2019

Application

AT2019766563T

15 May 2026

Publication

AT1914732T

IPC: A61K

Inventors: BOSE, NANDITA; BEATTY, GREGORY

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to the combination of β-glucan and a CD40 agonist for cancer immunotherapy. The combination therapy shows synergistic anti-tumor activity that is dependent on T cells. Surprisingly, the combination therapy is effective against poorly immunogenic tumors.

Need to check novelty before this filing date? Find Prior Art